Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07K14/165

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/165918UNIVERSAL ANTI-CORONAVIRUS CONSERVATIVE EPITOPE IGY AND BROAD-SPECTRUM ANTI-NOVEL CORONAVIRUS IGY AND COMPOSITE ANTIBODY
WO 11.08.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/CN2021/080581 Applicant SHENZHEN JASON INTELLIGENT BIOENGINEERING LTD. Inventor PAAU, Shing
Provided in the present invention are a universal anti-coronavirus conservative epitope IgY and a broad-spectrum anti-mutation novel coronavirus IgY, and a composite antibody and a combined preparation. Provided in the present invention is a method for preparing the universal anti-coronavirus conservative epitope IgY and the broad-spectrum anti-variation novel coronavirus IgY antibody and an anti-mutation novel coronavirus IgY antibody and the combined antibody. Furthermore, the IgY and the composite IgY and the combined antibody can bind to a coronavirus universal conservative epitope and an antigen epitope with strong conservation, to achieve a broad-spectrum neutralizing virus effect, and the problems of coronavirus and novel coronavirus being prone to variation and immune escape and treating an asymptomatic patient are solved. Further provided in the present invention are a central air conditioner atomizing disinfectant and outer packaging disinfectant and an aerosol inhalation, spray, oral spray, nasal spray, nasal drops, eye drops, air disinfectant, hand sanitizer, powder, tablet, mouth lozenge, oral liquid and capsule made from the IgY and the composite IgY, which are used in drugs, disinfection products, health-care products and medical devices for preventing and treating coronavirus and novel coronavirus infections.
2.WO/2022/170119ADJUVANTED MUCOSAL SUBUNIT VACCINES FOR PREVENTING SARS-COV-2 TRANSMISSION AND INFECTION
WO 11.08.2022
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/US2022/015349 Applicant THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Inventor BERZOFSKY, Jay A.
Immunogenic compositions that include SARS-CoV-2 spike (S) protein, S1 protein, or S2 protein, and an adjuvant, such as alum, or a combination of CpG oligodeoxynucleotide, Poly I:C, and IL-15, and nanoparticle compositions that include SARS-CoV-2 S protein, S1 protein, or S2 protein, and CpG oligonucleotide, poly(I:C), and IL-15, are provided. Also provided are methods of using such compositions, for example a prime intramuscular administration followed by one or more intranasal boosters that include the disclosed nanoparticles, to generate an immune response to SARS-CoV-2 in a subject, for example respiratory mucosal immunity, for example to prevent SARS-CoV-2 infection or transmission to other subjects.
3.WO/2022/161598ANTIBODIES BROADLY TARGETING CORONAVIRUSES AND USES THEREOF
WO 04.08.2022
Int.Class A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
Appl.No PCT/EP2021/051745 Applicant ETH ZURICH Inventor SALLUSTO, Federica
The present invention relates to antibodies, and antigen binding fragments thereof, that bind to the spike (S) protein of coronaviruses. The antibodies, and antigen binding fragments thereof, broadly target coronaviruses, including different alpha- and betacoronaviruses. The invention also relates to nucleic acids that encode, and to cells that express such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments in the treatment and diagnosis of coronavirus infection. Furthermore, a recombinant peptide, polypeptide or protein comprising the epitope, to which the antibodies bind to, is provided, which may be useful in vaccination.
4.WO/2022/161495RECOMBINANT SARS-COV-2 VACCINE
WO 04.08.2022
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No PCT/CN2022/075134 Applicant GENESAIL BIOTECH (SHANGHAI) CO., LTD. Inventor LIANG, Min
Provided are SARS-CoV-2 vaccines useful for treating or protecting a subject from infection by SARS-CoV-2. The SARS-CoV-2 vaccines contain nucleic acids encoding at least one type of S protein variant, and other factors useful for treating or protecting a subject from infection by SARS-CoV-2, or expression vectors or viruses containing such nucleic acids, or host cells containing such nucleic acids or expression vectors.
5.WO/2022/162165FOLD PROMOTERS AND THEIR USE FOR THE PRODUCTION AND STABILIZATION OF POLYPEPTIDES
WO 04.08.2022
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Appl.No PCT/EP2022/052087 Applicant MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER Inventor GÖRLICH, Dirk
The present invention relates to the recombinant production of a protein of interest in a prokaryotic host cell or eukaryotic host cell wherein the protein of interest is obtained in a correctly folded and stable form. The protein of interest may be a difficult-to-make polypeptide for use as a vaccine or a pharmaceutical. The protein of interest is co- expressed with or fused to a 'fold promoter', which may be a VHH antibody recognizing the said protein.
6.WO/2022/163647ORAL CORONAVIRUS INFECTION VACCINE
WO 04.08.2022
Int.Class C12N 1/21
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
20Bacteria; Culture media therefor
21modified by introduction of foreign genetic material
Appl.No PCT/JP2022/002677 Applicant NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY Inventor SHIRAKAWA, Toshiro
Provided is a vaccine that can be administered orally against coronavirus infection. A vaccine that can be administered orally against coronavirus infection can be provided by transformed bifidobacteria designed so as to present some or all of the proteins that constitute the coronavirus on the bifidobacterium surface layer. Transformed bifidobacteria designed so as to present some or all of the proteins that constitute the coronavirus on the bifidobacterium surface layer induce humoral immunity and cellular immunity by oral administration and can suppress any increase in severity of pneumonia, etc., even after viral infection.
7.WO/2022/162012ANTIBODIES BROADLY TARGETING CORONAVIRUSES AND USES THEREOF
WO 04.08.2022
Int.Class A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
Appl.No PCT/EP2022/051776 Applicant ETH ZURICH Inventor SALLUSTO, Federica
The present invention relates to antibodies, and antigen binding fragments thereof, that bind to the spike (S) protein of coronaviruses. The antibodies, and antigen binding fragments thereof, broadly target coronaviruses, including different alpha- and betacoronaviruses. The invention also relates to nucleic acids that encode, and to cells that express such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments in the treatment and diagnosis of coronavirus infection. Furthermore, a recombinant peptide, polypeptide or protein comprising the epitope, to which the antibodies bind to, is provided, which may be useful in vaccination.
8.WO/2022/159429METHODS FOR DIAGNOSIS AND TREATMENT OF COVID-19
WO 28.07.2022
Int.Class G01N 33/68
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
Appl.No PCT/US2022/012878 Applicant MARSHALL UNIVERSITY RESEARCH CORPORATION Inventor LI, Wei
Methods for diagnosis and treatment of COVID-19 acuity in a subject include the identification of a subject as having an increased expression level and/or activity of thymidine phosphorylase in a biological sample obtained from the subject. An effective amount of a therapeutic agent that reduces the expression level or activity of thymidine phosphorylase can the be administered to the subject.
9.WO/2022/159839MONOCLONAL ANTIBODIES AGAINST COROVAVIRUSES AND USES THEREOF
WO 28.07.2022
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2022/013565 Applicant THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. Inventor KREBS, Shelly
The present disclosure is directed to monoclonal antibodies, or antigen-binding fragments thereof, that bind to coronavirus spike proteins, including the spike protein of SARS-CoV-2. These antibodies demonstrate high affinity binding to epitopes on the coronavirus spike protein and/or broad cross-reactivity to the spike protein of various coronaviruses. Compositions comprising the anti-coronavirus antibodies, nucleic acids encoding for the antibodies, recombinant expression vectors, and host cells are also disclosed. The present disclosure is also directed to methods of diagnosing, preventing or treating coronavirus infections, including infections or disease caused by SARS-CoV-2.
10.3156252AGENT FOR INDUCING SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 IN LYOPHILIZED FORM (VARIANTS)
CA 25.07.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 3156252 Applicant FEDERAL STATE BUDGETARY INSTITUTION "NATIONAL RESEARCH CENTRE FOR EPIDEMIOLOGY AND MICROBIOLOGY NAMED AFTER THE HONORARY ACADEMICIAN N.F. GAMALEYA" OF THE MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION Inventor ZUBKOVA, OLGA VADIMOVNA
The invention relates to biotechnology, immunology and virology. The claimed agent can be used for the prevention of diseases caused by severe acute respiratory syndrome virus SARS-CoV-2.The technical aim of the claimed group of inventions is to create agents containing a single active component and along with this ensuring the effective induction of immune response to the SARS-CoV-2 virus among broad strata of the population.tris from 0.0180 to 0.0338sodium chloride from 0.1044 to 0.1957sucrose from 5.4688 to 10.2539magnesium chloride hexahydrate from 0.0015 to 0.0028EDTA from 0.0003 to 0.0005polysorbate-80 from 0.0037 to 0.0070water the remaining part.The technical result is the creation of an agent which ensures the development of humoral and cell-mediated immune responses to the SARS-Cov-2 virus among broad strata of the population.With that, the agent is intended for intranasal or intramuscular administration. Also, the agent can be administered concomitantly and simultaneously via intranasal and intramuscular routes.52Date Recue/Date Received 2022-04-06